Team B&C| NT
Lupin Ltd., entered Guinness World Records for creating the largest book sentence using books. The title was made with 5000 book copies to display the letters, ‘Heart Rate, Is it a Missing Link?’ The unusual record was made possible by collating hard copies of the books in a structured manner under the supervision of an official from Guinness World Records, London.
The pharmaceutical company undertook the task to create awareness on preventive care and treatment strategies for patients with an elevated heart rate. According to the WHO, India accounts for one-fifth of the total deaths occurring from stroke and ischemic heart disease. The record was monitored by an adjudicator from Guinness World Records.
Speaking on the occasion, Rajeev Sibal, president, India Region Formulation, Lupin Ltd., said, “We are delighted to set a Guinness World Records title which will help in raising awareness on heart rate and its connection to well-being. Blood pressure and sugar monitoring are prevalent the world over, however heart rate tracking needed to be one of the critical health indices as a measure of good health. Our endeavour was to bring this aspect to the fore amongst the medical fraternity and for this book to serve as a ready reckoner in India and overseas. We are thankful to our eminent cardiologists who participated in the making of this book and curating this event.”
The book has been conceptualized and authored by eight eminent practicing cardiologists, including Dr J C Mohan, Dr Monotosh Panja, Dr I Sathyamurthy, Dr Rajeev Agarwala, Dr Brian Pinto, Dr CK Ponde, Dr A Sreenivas Kumar and Dr BK Mahala, after multiple rounds of detailed deliberations with over 500 doctors from across the country.
The book interlinks elevated heart rate and the onset various heart disease manifestations. The 5,000 books that were part of the record-breaking event will be distributed to heart specialists and medical practitioners across the country.
Headquartered in Mumbai, Lupin, is present in over 100 markets in the US, India, South Africa and across Asia Pacific, Latin America, Europe and Middle-East regions. The company is the leader in the cardiovascular, anti-diabetic, and respiratory segments. It is also the third largest pharmaceutical company in the US by prescriptions.